Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasiaStatus:Awaiting developmentProgramme:Medical technologies guidanceExpected publication date: TBC
Axonics sacral neuromodulation system for treating refractory overactive bladder (MTG50)Product type:GuidanceProgramme:Medical technologies guidancePublished: 3 September 2020
Echolaser for BPHStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
GreenLight XPS for treating benign prostatic hyperplasia (MTG74)Product type:GuidanceProgramme:Medical technologies guidancePublished: 29 November 2022
Holmium laser prostatectomy (IPG17)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 26 November 2003
Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia (IPG475)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 January 2014
Laparoscopic augmentation cystoplasty (including clam cystoplasty) (IPG326)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 16 December 2009
Laparoscopic prostatectomy for benign prostatic obstruction (IPG275)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 26 November 2008
Lower urinary tract symptoms in men: management (CG97)Product type:GuidanceProgramme:Clinical guidelineLast updated: 3 June 2015Published: 23 May 2010
Mirabegron for treating symptoms of overactive bladder (TA290)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 June 2013
Optilume for treating recurrent bulbar urethral strictures (MTG73)Product type:GuidanceProgramme:Medical technologies guidancePublished: 29 November 2022
Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG611)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 April 2018
Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG737)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 21 September 2022
Prostatitis (acute): antimicrobial prescribing (NG110)Product type:GuidanceProgramme:NICE guidelinePublished: 31 October 2018
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)Product type:GuidanceProgramme:Medical technologies guidancePublished: 24 June 2020
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (IPG536)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 November 2015
Sacral nerve stimulation for urge incontinence and urgency-frequency (IPG64)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 June 2004
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2013
The PLASMA system for transurethral resection and haemostasis of the prostate (MTG53)Product type:GuidanceProgramme:Medical technologies guidancePublished: 6 January 2021
Transperineal laser ablation (TPLA) for treating lower urinary tract symptoms of benign prostatic hyperplasia using a ultra-micro invasive approach.Status:Awaiting developmentProgramme:Interventional procedures guidanceExpected publication date: 27 February 2025
Transurethral electrovaporisation of the prostate (IPG14)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 October 2003
Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG770)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 14 September 2023
Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG625)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 21 August 2018
TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MT512)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)Product type:GuidanceProgramme:Medical technologies guidancePublished: 4 May 2021
Vibegron for treating symptoms of overactive bladder ID6300Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC